Head-to-head · free

Stevanato Group S.p.A. vs TScan Therapeutics, Inc.

STVN vs TCRX — return on capital, cash generation, margins and balance sheet side by side.

STVN

2 / 3

measures where STVN leads

TCRX

1 / 3

measures where TCRX leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSTVNTCRX · FY2025
Revenue—$10.3M
Net income—(129.8M)
Revenue growth (yearly, multi-year)—0.5%
Free cash flow—(139.7M)
Free cash flow margin—-1353.3%
Net cash / (debt)——
ROIC7.7%—
Return on equity9.7%-71.3%
Gross margin29.0%—
Operating margin16.8%-1315.4%
Net debt / EBITDA1.13x0.90x

Figures are as reported by each company; latest fiscal year shown.

Where Stevanato Group S.p.A.'s cash went

Not reported yet.

Full STVN profile →

Where TScan Therapeutics, Inc.'s cash went (FY2025)

Capital spending
$4.4M
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TCRX profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons